GLUE

Monte Rosa Therapeutics, Inc.

Biotechnology · Biotechnology

$173.87 sample

-2.18 (-1.24%) 1D

Market cap

$122.7B

Price as of

2026-10-03

Latest filing

8-K · 2026-08-31

Alerts

8

Price$173.87 -3.13% 3M daily closessample

189.35163.17

2026-07-072026-07-292026-08-202026-09-102026-10-02

purchase / approvalsale / rejectionfiling / neutral

Latest events

Filings, trades, FDA; newest first

Sep 28INSInsider buy: General Counsel
Sep 22INSInsider sell: General Counsel
Sep 16INSInsider buy: Chief Financial Officer
Sep 09INSInsider sell: Chief Executive Officer
Aug 31SEC8-K filed: material event
Aug 25INSInsider sell: EVP, Operations
Aug 14INSInsider sell: General Counsel
Aug 05INSInsider buy: Chief Executive Officer

Sign up to see the real GLUE record →

Company facts

SEC EDGAR registration

Name: Monte Rosa Therapeutics, Inc.
Sector: Biotechnology
Industry: Biotechnology
Smart-money score: -42sample, -100 to +100
Reporting currency: USD

Who is positioning in GLUE

sample

Insiders: 23 insider transactions over 90 days, net selling, $261.9M
Congress: No member trades over 90 days
Institutions · 13F: 17 funds hold $2.2B
Activists · 13D/G: No 13D/13G activist filings on record

How are the fundamentals trending?

sample, by period end

Revenue$4.8B +17.2% y/y

Q4 2024Q3 2026

Inventory$2.9B +13.3% y/y

Q4 2024Q3 2026

Accounts receivable$2.2B +8.9% y/y

Q4 2024Q3 2026

Total debt$5.6B +5.4% y/y

Q4 2024Q3 2026

Peers

sample

Sample peer A: $79.0B +1.0% 3M
Sample peer B: $26.4B +14.3% 3M
Sample peer C: $20.3B +16.3% 3M
Sample peer D: $95.9B +8.5% 3M
Sample peer E: $24.4B -7.4% 3M